The headline beat is significant but driven by a one-time $55.7M licensing fee, not core ORLADEYO acceleration. ORLADEYO guidance was maintained, not raised, suggesting limited upside to the base business. The lowered opex guidance and pipeline rationalization are credit-positive for cash flow. Watch for navenibart ALPHA-ORBIT data in Q3 2027 as the next major catalyst; the pediatric ORLADEYO pellet launch is a near-term volume driver to monitor.
Drugs in focus
BCRX drug pipeline →navenibart
◆ Mixed Named in this 8-K- Impact
- Phase
- Phase 3
- Time to market
- Assuming positive Phase 3 data (Q3 2027), a US regulatory filing would follow around end-2027, with potential approval in 2028-2029.
- Next catalyst
- None dated
What to watchNavenibart is a promising long-term pipeline story within BioCryst, but there is no imminent binary catalyst for ~12+ months. Investors should watch for interim data updates at medical conferences and the pivotal Phase 3 ALPHA-ORBIT readout in Q3 2027. In the meantime, near-term BCRX value is driven by ORLADEYO commercial execution and the ongoing business restructuring.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 5 $9.07entry
- T+1 · 3mo ago +2.54%α +2.70% · $9.30
- T+5 · 3mo ago +16.76%α +16.41% · $10.59
- T+20 · 3mo ago +12.13%α +12.73% · $10.17
- T+60 · 19d ago −6.73%α −6.92% · $8.46
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
BioCryst reported Q2 2026 GAAP EPS of $0.30, beating the $0.23 consensus by 30.4%, and total revenue of $218.3M, beating the $183.3M estimate by 19.1%. The beat was driven by a $55.7M navenibart licensing fee from Neopharmed Gentili, while core ORLADEYO revenue grew only 1% YoY to $158.2M. The company raised total revenue guidance to $690M-$715M and lowered non-GAAP opex guidance, but maintained ORLADEYO guidance at $625M-$645M, signaling the core business is not accelerating.
Key Financial Metrics
Key Facts
- GAAP EPS of $0.30 beat consensus of $0.23 by 30.4%
- Total revenue of $218.3M beat consensus of $183.3M by 19.1%
- ORLADEYO revenue of $158.2M grew only 1% YoY (10% on comparable basis ex-Europe)
- Recognized $55.7M of navenibart licensing revenue from Neopharmed Gentili upfront payment
- Raised full-year 2026 total revenue guidance to $690M-$715M (from $635M-$660M)
- Maintained ORLADEYO revenue guidance at $625M-$645M
- Lowered non-GAAP operating expense guidance to $420M-$440M (from $450M-$470M)
- GAAP operating profit of $98.5M; Non-GAAP operating profit of $113.2M
- Cash, cash equivalents and investments totaled $352.6M at June 30, 2026
- Completed enrollment in ALPHA-ORBIT pivotal navenibart study; top-line data expected Q3 2027
- Began shipping ORLADEYO oral pellets to pediatric patients on August 3, 2026
- Announced discontinuation of internal discovery programs and closure of Birmingham facility
Financial Impact
Q2 2026 GAAP EPS of $0.30 vs $0.23 consensus (beat by $0.07); total revenue of $218.3M vs $183.3M consensus (beat by $35.0M)
Risk Factors
- Core ORLADEYO revenue growth is decelerating (1% YoY reported, 10% comparable) and guidance was not raised
- Navenibart is still investigational with pivotal data not expected until Q3 2027, binary risk
- Restructuring/discontinuation of internal discovery programs may signal limited pipeline depth
- Stockholders' deficit of $454.3M and accumulated deficit of $2.15B indicate ongoing balance sheet weakness
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001171843-26-005223 |
| Document: f8k_080526.htm | 0001171843-26-005223 |
| Document: 0001171843-26-005223-index-headers.html | 0001171843-26-005223 |
| Document: 0001171843-26-005223-index.html | 0001171843-26-005223 |
| Document: 0001171843-26-005223.txt | 0001171843-26-005223 |
| 8-K Data (Synthetic) | 0001171843-26-005223 |
Track record
20 reports on BCRX
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $7.71 Now $7.45 −3.35% settles Feb 16
- Nov 13, 20263d ago Press Release Neutral 3/10 Entry $7.61 Now $7.45 −2.10% settles Feb 11
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $7.53 Now $7.45 −1.06% settles Feb 8
- Nov 4, 202612d ago 8-K Bullish 6/10 No price data
- Nov 4, 202612d ago Press Release Bullish 6/10 Entry $8.24 Now $7.45 −9.59% settles Feb 2
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $8.57 Now $7.45 −13.07% settles Feb 1
- Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $8.37 Now $7.45 −10.99% settles Jan 26
- Oct 21, 202626d ago Press Release Neutral 1/10 Entry $7.78 Now $7.45 −4.24% settles Jan 20
- Aug 5, 202614w ago 8-K Bullish 7/10 Viewing Entry $9.07 to $8.46 Now $7.45 −17.86% ▼ −6.73% −6.92% vs SPY
- Jun 29, 202620w ago 8-K Neutral 5/10 Entry $9.55 to $8.78 Now $7.45 −21.99% ▼ −8.06% −12.45% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers